Onda (Ondansetron)

Ondansetron, the active ingredient in Onda, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for systemic use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy and surgery in adult and pediatric patients. GNH USA supplies Onda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Onda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is used to control nausea and vomiting that arise from several therapeutic pathways.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: helps maintain patient comfort during and after treatment. - Post‑operative nausea and vomiting: decreases the need for rescue anti‑emetics after surgery. - Pregnancy‑related hyperemesis gravidarum: provides relief when other measures are insufficient. - Anticipatory nausea: lessens conditioned nausea in patients with a history of severe chemotherapy‑induced vomiting.

Side effects are generally mild but can vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals. - Neuroleptic malignant‑like reactions: extremely rare but potentially life‑threatening.

Before prescribing Ondansetron, clinicians should assess patient‑specific risk factors and follow safe handling practices.

- Cardiac monitoring: avoid in patients with known prolonged QT interval or electrolyte disturbances. - Electrolyte balance: correct hypokalaemia, hypomagnesaemia or hypocalcaemia before use. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Pregnancy and lactation: use only if benefit outweighs potential risk. - Store at ambient temperature: keep below 25 °C, retain original packaging and protect from moisture.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomorphine: concurrent use can cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., codeine, tramadol): potential for altered analgesic effect. - Serotonergic agents (e.g., SSRIs, MAOIs): monitor for serotonin syndrome. - Diuretics causing electrolyte loss: watch for QT‑related cardiac events.